Business Context and Reporting Period
Company: Neogen Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: May 31, 2006
Business Overview: Neogen develops, manufactures, and markets products dedicated to food and animal safety. Operations are divided into two primary segments: Food Safety (diagnostic test kits for pathogens, toxins, and allergens) and Animal Safety (pharmaceuticals, rodenticides, vaccines, and veterinary instruments). The company operates manufacturing facilities in the U.S. (Michigan, Kentucky, Wisconsin, Florida) and Scotland.
Key Financial Metrics
| Metric | Fiscal 2006 | Fiscal 2005 | Change |
|---|---|---|---|
| Net Sales | $72,433,000 | $62,756,000 | +15% |
| Gross Margin | $37,006,000 (51.1%) | $30,603,000 (48.8%) | +21% |
| Operating Income | $12,045,000 (16.6%) | $8,769,000 (14.0%) | +37% |
| Net Income | $7,941,000 | $5,916,000 | +34% |
| Diluted EPS | $0.92 | $0.70 | +31% |
| Cash from Operations | $12,313,000 | $6,722,000 | +83% |
| Working Capital | $26,252,000 | $22,644,000 | +16% |
| Long-Term Debt | $9,955,000 | $0 | New Facility |
Segment Performance: Food Safety sales were $34.95 million (48.3% of total), up 24%. Animal Safety sales were $37.48 million (51.7% of total), up 8%. International sales accounted for 28.6% of total revenue.
Material Changes vs. Prior Period
- Acquisitions: Significant revenue growth was driven by the December 2005 acquisition of the dairy antibiotic testing business of UCB and the February 2006 acquisition of Centrus International Inc. (Soleris product line). These acquisitions added approximately $10.3 million in goodwill and intangible assets.
- Margin Expansion: Gross margins improved to 51% from 49% in 2005. This was attributed to favorable product mix changes, the realization of efficiencies from new manufacturing facilities, and the internal production of ATP sanitation tests (previously outsourced).
- Debt Structure: The company incurred $9.955 million in long-term debt under a new $17.5 million revolving credit facility in December 2005 to fund acquisitions and operations. This debt was repaid in June 2006 following a stock offering.
- Inventory: Inventory levels increased 28% ($3.83 million) primarily due to the acquisitions.
Guidance, Outlook, and Risks
Management Commentary: Management does not provide specific financial forecasts. The outlook remains optimistic, focusing on internal growth, new product introductions (expected 2007-2009), and strategic acquisitions. The company maintains an active acquisition program.
Subsequent Event: On June 2, 2006, the company completed an offering of 800,000 shares (650,000 by the company), raising approximately $12.2 million in net proceeds. These funds were used to repay the long-term debt and add to working capital.
Risks and Contingencies:
- Acquisition Integration: Success depends on effectively integrating acquired businesses; failure could materially adversely affect results.
- Competition: Intense competition exists in both food and animal safety markets, with competitors possessing greater financial resources.
- Regulatory: Products are subject to regulation by the USDA and FDA. Changes in regulations could impact revenues or costs.
- Intellectual Property: The company relies on patents and trade secrets; infringement litigation or failure to protect IP could harm the business.
- Environmental: The company has an environmental remediation liability of approximately $1.0 million (net present value) at its Randolph, Wisconsin facility.
Investor Verification Checklist
- Debt Repayment: Verify the repayment of the $9.955 million credit facility using proceeds from the June 2006 stock offering.
- Acquisition Accounting: Confirm the finalization of purchase accounting for the UCB and Centrus acquisitions, as goodwill and intangible asset valuations were preliminary.
- Stock Offering Dilution: Assess the impact of the 650,000 new shares issued in June 2006 on future earnings per share.
- Environmental Liability: Monitor the status of the environmental remediation at the Randolph, Wisconsin facility and associated cash outflows.
- International Exposure: Review the impact of foreign currency fluctuations on the 28.6% of revenue derived from international sales.